Cogent Biosciences Enters Material Agreement, Files 8-K
Ticker: COGT · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $32.00, $1.00, $336,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, filing
TL;DR
Cogent Biosciences just signed a big deal and filed an 8-K. Watch this space.
AI Summary
On September 5, 2025, Cogent Biosciences, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. Financial statements and exhibits are included as part of this report.
Why It Matters
This filing signals a significant new contract or financial commitment for Cogent Biosciences, potentially impacting its financial obligations and strategic direction.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks and opportunities that require careful evaluation.
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- September 5, 2025 (date) — Date of Earliest Event Reported
FAQ
What is the nature of the material definitive agreement entered into by Cogent Biosciences?
The filing states that Cogent Biosciences, Inc. entered into a material definitive agreement on September 5, 2025, but the specific details of the agreement are not provided in this summary.
What type of financial obligation has Cogent Biosciences created?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant, but the specifics are not detailed here.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 5, 2025.
What other information is included with this 8-K filing?
This 8-K filing includes financial statements and exhibits.
What was Cogent Biosciences' former company name?
Cogent Biosciences, Inc. was formerly known as Unum Therapeutics Inc. and Unum Therapeutics, Inc., with name changes occurring on April 2, 2018, and October 14, 2014, respectively.
Filing Stats: 918 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-09-11 16:30:26
Key Financial Figures
- $0.001 — ange on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se
- $32.00 — Commencement Date at an initial rate of $32.00 per square foot. Rent will be payable i
- $1.00 — ents and subject to annual increases of $1.00 per square foot over the term. Addition
- $336,000 — f credit in the amount of approximately $336,000 as a security deposit. The foregoing
Filing Documents
- d947118d8k.htm (8-K) — 29KB
- d947118dex101.htm (EX-10.1) — 432KB
- 0001193125-25-201353.txt ( ) — 670KB
- cogt-20250905.xsd (EX-101.SCH) — 3KB
- cogt-20250905_lab.xml (EX-101.LAB) — 18KB
- cogt-20250905_pre.xml (EX-101.PRE) — 11KB
- d947118d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Lease Commencement Date, completion of construction of the Lease Space, rent payments and anticipated tenant improvement costs. These forward-looking statements are based on Cogent's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks, uncertainties and contingencies related to the construction of the Leased Space. A further description of the risks and uncertainties relating to Cogent's business is contained in its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC. Cogent undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Lease by and between Cogent Biosciences, Inc. and BP THIRD AVENUE LLC dated September 5, 2025. Filed herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2025 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer and Corporate Secretary